15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Sensus Healthcare Inc, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $6.00 to $8.00, so the covering firms are broadly aligned. The average target of $6.67 sits 119% above the current $3.04. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.06 next quarter toward $-0.09 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Sensus Healthcare Inc.
As of Jul, 3 of 3 firms rate SRTS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SRTS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.06
Range $-0.07 – $-0.06 · 3 analysts · +6% YoY
Next period, 3 analysts expect Sensus Healthcare Inc to earn $-0.06 a share (range $-0.07 – $-0.06), versus $-0.06 a year earlier. Full-year consensus is $-0.33, growing to $-0.09 the year after.
REVENUE · NEXT QUARTER
$6.2M
Range $4.7M – $7.0M · 3 analysts · -10% YoY
Revenue is expected to reach $6.2M (range $4.7M – $7.0M), -9.5% year-over-year. Full-year consensus is $22.0M, rising to $31.3M next year.
Top analysts covering Sensus Healthcare Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SRTS.
#1
Yi Chen
HC Wainwright & Co. · Rank #238
Buy
$8.00+163.2% to target
Overall win rate
34%
+ Follow
#2
Anthony Vendetti
Maxim Group · Rank #281
Buy
$6.00+97.4% to target
Overall win rate
30%
+ Follow
#3
BH
Ben Haynor
Lake Street
Buy
$6.00+97.4% to target
Coverage
—
+ Follow
#4
JW
Jason Wittes
Roth MKM
Buy
$10.00+228.9% to target
Coverage
—
+ Follow
SRTS stock forecast FAQ
What is SRTS's average 12-month price target?+
The 3 analysts with a live target average $6.67 for Sensus Healthcare Inc over the next 12 months, ranging from a $8.00 high to a $6.00 low.
Is SRTS stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SRTS?+
The Street-high target is $8.00 (HC Wainwright & Co.), and the Street-low is $6.00 (Maxim Group). The average of all 3 active targets is $6.67.
How many Wall Street analysts cover SRTS?+
3 analysts have an active rating on Sensus Healthcare Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering SRTS?+
Among analysts who currently cover SRTS, Yi Chen of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #238). Their current call is Buy with a $8.00 target.
What is Sensus Healthcare Inc's projected EPS for next quarter?+
The consensus estimate is $-0.06 per share (range $-0.07 – $-0.06) across 3 analysts. Full-year EPS is projected at $-0.33, rising to $-0.09 the following year.
How much revenue is Sensus Healthcare Inc expected to report next quarter?+
Consensus revenue is $6.2M (range $4.7M – $7.0M). Full-year revenue is projected at $22.0M, growing to $31.3M next year.
Have analysts been upgrading or downgrading SRTS lately?+
As of Jul, 3 of 3 firms rate SRTS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SRTS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
